Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Total Non-Current Liabilities of $902.9 million for Q1 2026, up 5.02% year-over-year from $859.7 million in Q1 2025, and little changed quarter-over-quarter from $899.0 million in Q4 2025.
Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Total Non-Current Liabilities for 6 consecutive years, with $902.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 5.02% year-over-year to $902.9 million; the TTM figure through Mar 2026 stood at $902.9 million (up 5.02% YoY), while the FY2025 annual figure was $899.0 million, up 7.0% from the prior year.
- Total Non-Current Liabilities steadied at $902.9 million in Q1 2026 per VRNO's latest filing, from $899.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $902.9 million in Q1 2026 and bottomed at $469.5 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $736.3 million across 5 years, with a median of $680.7 million in 2023.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 43.17% — and 2024, when it slipped 4.02%.
- Verano Holdings' Total Non-Current Liabilities stood at $667.9 million in 2022, then slipped by 0.21% to $666.5 million in 2023, then increased by 26.06% to $840.2 million in 2024, then increased by 7.0% to $899.0 million in 2025, then rose by 0.44% to $902.9 million in 2026.
- Business Quant data shows VRNO's Total Non-Current Liabilities at $902.9 million in Q1 2026, $899.0 million in Q4 2025, and $897.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Verano Holdings | 440.28 Mn | 355.08 Mn | 99.70 Mn | 915.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 915.16 Mn |
| Mar 31, 2026 | 902.87 Mn |
| Dec 31, 2025 | 898.95 Mn |
| Sep 30, 2025 | 897.85 Mn |
| Jun 30, 2025 | 868.42 Mn |
| Mar 31, 2025 | 859.73 Mn |
| Dec 31, 2024 | 840.17 Mn |
| Sep 30, 2024 | 661.59 Mn |
| Jun 30, 2024 | 657.07 Mn |
| Mar 31, 2024 | 661.13 Mn |
| Dec 31, 2023 | 666.48 Mn |
| Sep 30, 2023 | 689.32 Mn |
| Jun 30, 2023 | 672.14 Mn |
| Mar 31, 2023 | 669.11 Mn |
| Dec 31, 2022 | 667.86 Mn |
| Sep 30, 2022 | 698.54 Mn |
| Jun 30, 2022 | 469.47 Mn |
| Dec 31, 2021 | 596.33 Mn |